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Background: Increasing evidence of autoimmune phenomena in some individuals with autism could represent the
presence of altered or inappropriate immune responses in this disorder. The role of the nucleosome in the induction of
antibody response in some autoimmune-mediated tissue damage may provide novel targets for treatment. Due to the
paucity of studies investigating the frequency of systemic auto-antibodies in autism, we are the first to investigate the
frequency of antinucleosome-specific antibodies in a group of autistic children.
Methods: Serum antinucleosome-specific antibodies were measured by ELISA in 60 autistic children, between the ages
of 3 and 12 years, in comparison to 60 healthy children. Autistic severity was assessed using the Childhood Autism
Rating Scale (CARS).
Results: Autistic children had significantly higher serum antinucleosome-specific antibodies than healthy children
(P <0.001). The seropositivity of antinucleosome-specific antibodies was found in 46.7% of autistic children. Autistic
children with a family history of autoimmunity (40%) had a significantly higher frequency of serum
antinucleosome-specific antibodies (83.3%) than patients without such a history (22.2%, P <0.001).
Conclusions: Serum levels of antinucleosome-specific antibodies were increased in some autistic children. However,
these data should be treated with caution until further investigations are performed with a larger subject population to
determine whether these antibodies have a role in the induction of autoimmunity in a subgroup of autistic children.
The role of immunotherapy in children with autism should be also studied.
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A possible role of immune system abnormalities in the
pathogenesis of some neurologic disorders, including
autism, was postulated. Autoimmunity to the central
nervous system is the most common of these abnormal-
ities [1,2]. Brain-specific auto-antibodies were detected
in the sera of many autistic children [3-10]. In addition,
autoimmune disorders are increased in families of some
children with autism [11-14]. There is a strong associ-
ation between autism and the major histocompatibility
complex for the null allele of C4B in the class III region.
This results in low production of C4B protein, leading to
repeated infections that play an important role in the* Correspondence: gehan.mostafa2000@yahoo.com
1Autism Research and Treatment Center, AL-Amodi Autism Research Chair,
Department of Physiology, Faculty of Medicine, King Saud University, Riyadh,
Saudi Arabia
2Department of Pediatrics, Faculty of Medicine, Ain Shams University, 9
Ahmed El-Samman Street off Makram Ebaid, Nasr City 11511 Cairo, Egypt
© 2014 AL-Ayadhi and Mostafa; licensee BioM
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.development of autoimmunity [15-18]. Some autistic
children have an imbalance of T helper (Th)1/Th2 sub-
sets toward Th2, which are responsible for allergic re-
sponse and production of autoantibodies [1].
One of the common serological hallmarks of auto-
immune disorders is the presence of various autoanti-
bodies in the sera of patients affected by these disorders
[19]. The presence of abnormal levels of autoantibodies
to intracellular antigens is a hallmark of several auto-
immune diseases [20].
Evidence accumulated in recent years suggests that the
nucleosome, the fundamental unit of chromatin and a
normal product of cell apoptosis, plays a key role in
some autoimmune diseases as it is a major target auto-
antigen for autoantibody mediated tissue lesions [21,22].
The broad antinucleosome antibody family includes: the
nucleosome-specific antibodies (antinucleosome anti-
bodies without anti ds-DNA and antihistone reactivities),ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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activity, and the antinucleosome antibodies with antihis-
tone reactivity [23]. Anti ds-DNA antibodies account for
a minor part (<30%) of the serum antinucleosome re-
activity in lupus patients and nucleosome-specific auto-
antibodies are in large excess over anti ds-DNA in lupus
patients [24].
Due to the paucity of studies investigating the fre-
quency of systemic auto-antibodies in autism, we are the
first to investigate the frequency of antinucleosome-
specific antibodies in a group of autistic children.
Methods
Study population
This case-control study was conducted on 60 children
who had classic-onset autism, over a period of 6 months
from the beginning of June 2013 to the end of November
2013. The autistic group comprised 49 male and 11 female
patients recruited from the Autism Research and Treat-
ment Center, Faculty of Medicine, King Saud University,
Riyadh, Saudi Arabia. Patients fulfilled the criteria for
the diagnosis of autism according to the 4th edition
of the Diagnostic and Statistical Manual of Mental
Disorders [25]. Their ages ranged from 3 to 12 years
(median (IQR) = 7 (3) years). Patients who had associated
neurological diseases (such as cerebral palsy and tuberous
sclerosis) or metabolic disorders (such as phenylketonuria)
were excluded from the study.
The control group comprised 60 age- and sex-matched
apparently healthy children. They included 50 male and
10 female children. They were the healthy older siblings of
the healthy infants who attend the Well Baby Clinic, King
Khalid University Hospital, Faculty of Medicine, King
Saud University, Riyadh, Saudi Arabia for routine follow-
up of their growth parameters. The control children were
not related to the children with autism and demonstrated
no clinical findings suggestive of immunological or neuro-
psychiatric disorders. Their ages ranged from 3 to 12 years
(median (IQR) = 6 (4) years).
This study was approved by the local Ethical Committee
of the Faculty of Medicine, King Saud University, Riyadh,
Saudi Arabia. In addition, an informed written consent of
participation in the study was signed by the parents or the
legal guardians of the all studied subjects.
Study measurements
Clinical evaluation of autistic patients
This was based on clinical history taking from care-
givers, clinical examination and neuropsychiatric assess-
ment. In addition, assessment of the disease severity was
done using the Childhood Autism Rating Scale (CARS)
[26], which rates the child on a scale from one to four in
each of fifteen areas (relating to people; emotional re-
sponse; imitation; body use; object use; listening response;fear or nervousness; verbal communication; non-verbal
communication; activity level; level and consistency of in-
tellectual response; adaptation to change; visual response;
taste, smell and touch response; and general impressions).
According to this scale, children who have scored 30 to 36
have mild to moderate autism (n = 31), while those with
scores ranging from 37 to 60 points have severe autism
(n = 29).
In addition, a family history of autoimmune diseases in
controls and children with autism was ascertained in an
identical fashion, but not in a blinded manner, by an ex-
pert rheumatologist. Parents were asked to fill out a
questionnaire regarding which first- (parents and sibs)
or second-degree relatives (grandparents, uncles and
aunts) had received a diagnosis of specified autoimmune
disorders. A list of autoimmune diseases with descrip-
tions was provided. There was a verification of the diag-
nosis of autoimmune diseases via medical record review.
The disorders inquired about in the questionnaire in-
cluded rheumatoid arthritis, juvenile rheumatoid arth-
ritis, systemic lupus erythematosus, insulin-dependent
diabetes mellitus, rheumatic fever, vasculitis, ankylosing
spondylitis, dermatomyositis, polymyositis, scleroderma,
uveitis, Sjogren’s syndrome, polyarteritis nodosa, Wegener’s
granulomatosus, Takayasu’s arteritis, psoriasis, multiple
sclerosis, vitiligo, myasthenia gravis, amyotrophic lat-
eral sclerosis, Crohn’s disease, ulcerative colitis, auto-
immune thyroiditis, idiopathic thrombocytopenic purpura,
Addison’s disease, pemphigus, and Guillain-Barre syn-
drome. These disorders were chosen because all have a
known or suspected autoimmune cause.
Measurement of antinucleosome-specific antibodies
This was performed by the ELISA technique (EURO-
IMMUN Medizinische Labordiagnostika AG, Germany)
[27]. The samples were run randomly in a blinded fash-
ion and they were run together, in parallel on the same
run with the same internal standards. Antibodies to
highly purified human nucleosomes (antinucleosome-
specific antibodies), if present in diluted serum, would
bind in the microwells. Washing the microwells removes
unbound serum antibodies. Horseradish peroxidase con-
jugated anti-human IgG immunologically binds to the
bound patient antibodies, forming a conjugate/antibody/
antigen complex. When substrate is washed in the pres-
ence of bound conjugate, it is hydrolyzed to form a blue
color. The addition of an acid stops the reaction, resulting
in a yellow end product. The intensity of this yellow color
is measured photometrically at 450 nm. The amount of
color is directly proportional to the concentration of
IgG antibodies present in the original sample. To in-
crease accuracy, all samples were analyzed twice in
two independent experiments to assess interassay varia-
tions and to ensure reproducibility of the observed results
Table 2 Serum levels of antinucleosome-specific antibodies





Healthy children (n = 60) 1.7 (1) 5.6
Autistic patients (n = 60) 2.9 (2.6) (<0.001)
Mild to moderate autism
(n = 31)
3.4 (3) 0.4
Severe autism (n = 29) 2.8 (2.7) (0.62)
IQR, interquartile range.
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Statistical analysis
The results were analyzed by a commercially available
software package (Statview; Abacus Concepts, Inc., Berk-
ley, CA, USA). The data were non-parametric; thus, they
were presented as median and interquartile range (IQR),
which are between the 25th and 75th percentiles. A
Mann- Whitney test was used for comparison between
these data. A chi-square test was used for comparison
between qualitative variables of the studied groups. A
Spearman’s rank correlation coefficient ‘r’ was used to
determine the relationship between different variables.
For all tests, a probability (P) of less than 0.05 was consid-
ered significant. As data distribution was non-parametric,
serum antinucleosome-specific antibodies levels were con-
sidered to be elevated if there levels were above the 95th
percentile of the healthy control values (3.49 U/l).
Results
The characteristics of the study subjects are shown in
Table 1.
Serum levels of antinucleosome-specific antibodies in
healthy children and patients with autism
Autistic children had significantly higher serum levels of
antinucleosome-specific antibodies than healthy con-
trols, P <0.001 (Table 2). According to the highest cut-
off value of serum antinucleosome-specific antibodies,
increased serum levels of antinucleosome-specific anti-
bodies were found in 46.7% (28/60) of autistic children.
On the other hand, there was a nonsignificant differ-
ence between serum levels of antinucleosome-specific
antibodies of children with mild to moderate autism and
patients with severe autism, P = 0.62 (Table 2). Also,






Age (in years) 7 (3) 6 (4)
Sex (male/female) 49/11 50/10
Family history of autoimmune
diseases
24/60 (40%) 5/60 (8.3%)




Systemic lupus erythematosus 3 1
Autoimmune thyroiditis 2
Rheumatic fever 1statistical difference between them in serum levels of
antinucleosome-specific antibodies (P = 0.32). Serum levels
of antinucleosome-specific antibodies had significant cor-
relations neither with the age of autistic children (P = 0.48)
nor with CARS (P = 0.50).
A family history of autoimmune diseases in patients
with autism and its relation to the frequency of
antinucleosome-specific antibodies
Twenty-four children with autism (40%) had a first- or
a second-degree relative with an autoimmune disease
(rheumatoid arthritis in 14 patients, insulin-dependent
diabetes mellitus in 4 patients, systemic lupus erythema-
tosus (SLE) in 3 patients, autoimmune thyroiditis in 2
patients and rheumatic fever in 1 patient), Table 1. Six
out of the 24 autistic children with a family history of
autoimmune disease (25%) had a mother with an auto-
immune disease (three had rheumatoid arthritis, one
had SLE, one had insulin-dependent diabetes mellitus
and one had autoimmune thyroiditis).
On the other hand, a family history of autoimmune
diseases was found in 5 of the studied 60 (8.3%) healthy
children (rheumatoid arthritis in 3 children, SLE in 1
child and insulin-dependent diabetes mellitus in 1 child),
Table 1. None of the healthy children with a family his-
tory of autoimmune disease had a mother with such
diseases. The frequency of autoimmune diseases among
families of children with autism was significantly higher
than normal children (P <0.001).
Autistic children with a family history of auto-
immunity had significantly higher frequency of serum
antinucleosome-specific antibodies (83.3%) than patients
without such a history, (22.2%, P <0.001) (Table 3).
Discussion
Autoimmunity may have a role in the pathogenesis of
autism. Immune system dysfunction may represent novel
targets for treatment in autism [1-3]. In our series, autis-
tic children had significantly higher serum levels of
antinucleosome-specific antibodies than healthy controls
(P <0.001). According to the highest cut-off value of
Table 3 The frequency of antinucleosome-specific
antibodies in relation to a family history of autoimmune
diseases in autistic patients







A positive family history of
autoimmune diseases (n = 24)
20 (83.3%) 4 (16.7%) 21.6
No family history of autoimmune
diseases (n = 36)
8 (22.2%) 28 (77.8%) (<0.001)
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levels of these antibodies were found in 46.7% of autistic
children. We could not trace data in literature regarding
the frequency of antinucleosome-specific antibodies in
children with autism to compare with our results.
Pathological T cell clones that recognize double-
stranded DNA and nucleosomes further drive B cell pro-
duction of anti-DNA and antinucleosome autoantibodies.
Deposition of these autoantibodies within the brain and
other organ systems contributes to the pathophysiology
and clinical manifestations of autoimmune diseases such
as SLE [28]. Complement-fixing IgG autoantibodies in-
cluding anti-DNA and antinucleosome antibodies may
cross the blood-brain barrier and combine with brain tis-
sue antigens to form immune complexes that damage the
neurological tissue in autistic patients [4].
The term ‘nucleosome’ defines a basic unit of chromatin.
Each nucleosome consists of 146 base pairs of double
stranded DNA, wrapped twice around a histone octamer, a
protein core. A histone octamer consists of two molecules
each of histones H2A, H2B, H3, and H4. In chromatin, nu-
cleosomes are connected by 15 to 80 base pairs of linker
DNA, to which histone H1 is attached. Anti-dsDNA and
anti-histone antibodies belong to the nucleosome family as
do antinucleosome-specific antibodies, since nucleosomes
share several common epitopes with dsDNA and histones.
Nucleosome-specific antibodies do not react with the indi-
vidual components of the nucleosome (that is, DNA and
histones) but recognize conformational epitopes resulting
from interactions between the DNA and histone [29]. Nu-
cleosomes are generated in vivo by the process of apop-
tosis, which is disturbed in some autoimmune diseases
such as SLE. Nucleosomes are the major target autoanti-
gens for autoantibodies mediating tissue lesions, especially
glomerulonephritis in SLE [30,31]. Previous studies have
reported that antinucleosome antibody reactivity is a very
sensitive marker of SLE [32-37]. Similarly, it has been re-
ported that 30% of SLE patients with high antinucleosome-
specific antibody reactivity have little, if any, anti ds-DNA
or antihistone reactivity [34].
The mechanisms that lead to the induction of antinu-
cleosome specific autoantibodies in some autoimmunediseases remain obscure. In view of the prominence of
nucleosomes which circulate at high levels in some auto-
immune diseases such as SLE [38], it has been specu-
lated that highly accelerated rates of apoptosis [39], and/
or abnormal sites or abnormal processing of apoptotic
cells could lead to autoantibody production [40]. Also,
nucleosomes may elicit the production of interleukin-6
and stimulation of lymphoproliferation and IgG synthe-
sis by splenic B cells. This could result in a polyclonal
activation that triggers both a specific (nucleosome-
driven) and nonspecific antibody production [38]. Alter-
ation of the selected parameters confirm the role of apop-
tosis and neuroinflammation mechanisms in the etiology
of autism [41]. The apoptotic marker soluble fatty acid
synthase antigen was reported to be high in Saudi children
with severe autism, and can be considered an indicator of
disease severity [42]. Disturbances in brain glutathione
homeostasis may contribute to oxidative stress, immune
dysfunction and apoptosis, particularly in the cerebellum
and temporal lobe, and may lead to neurodevelopmental
abnormalities in autism [43]. Thus, accelerated rates of
apoptosis in autism, like in SLE, may be the possible rea-
son behind the increased frequency of antinucleosome-
specific autoantibodies in some autistic children as shown
in this study. Additional investigation designed to expand
on these data is warranted.
Other possible reasons behind the initiation of auto-
immunity and the production of autoantibodies in some
autistic children may be attributed to the exposure to
some environmental cross-reacting antigens, which initi-
ate autoimmune reactions in genetically susceptible indi-
viduals [4]. These environmental antigens include food
allergies to certain peptides as casein of milk and gluten
of wheat [44,45], heavy metals exposure [46,47] and
Hevea brasiliensis proteins in natural rubber latex [48]. In
addition, infectious agents (for example, virus-induced
autoimmunity) may play a causal in autism [1,49].
Studies investigating the frequency of systemic anti-
bodies in autism are very few. Seropositivity of antinu-
clear antibodies was reported in only 20% of 80 Egyptian
children with autism, and this percentage was signifi-
cantly higher than healthy children (2.5%) [7]. Brain spe-
cific autoantibodies were reported in sera of a large
proportion of children with autism [4-10]. This may be
attributable to the imbalance of T helper (Th)1/Th2 sub-
sets toward Th2, which are responsible for the production
of antibodies and allergic response, in some children with
autism [1]. In 2008, Mostafa and associates [6] reported
seropositivity for antimyelin-associated glycoprotein anti-
bodies in 62.5% of a group of 32 Egyptian autistic children
between 3 and 8 years of age.
The explanation of the lower percentage of sys-
temic antibodies (such as antinuclear antibodies and
antinucleosome-specific antibodies) than the percentage
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[4-10] may be explained by the fact that autoimmunity
in autism is organ-specific (that is, to brain) and not
multisystemic. Diseases with multisystem autoimmun-
ity (for example, SLE) have an increased frequency of
systemic antibodies (such as antinuclear antibodies and
antinucleosome-specific antibodies) and in these diseases,
measurement of systemic antibodies is a reliable screening
test [14]. Thus, testing for brain-specific autoantibodies
seems to be more reliable than an antinucleosome-specific
antibodies test in screening for autoimmunity in autism.
To further understand if autoimmunity could play a
role in autism, we studied the frequency of autoimmune
diseases in families of patients with autism in compari-
son to healthy children. The frequency of autoimmune
disease among families of the former group (40%) was
significantly higher than that of the latter group (8.3%).
Previous research had also found an increased frequency
of autoimmunity in families of children with autism
compared to those of healthy and autoimmune control
subjects [11-15]. In one study [11], a family history of
autoimmune diseases was reported in 46% of children
with autism. They also reported that as the number of
family members with autoimmune disorders increased
from one to three, the risk of autism was greater with an
odds ratio that increased from 1.9 to 5.5, respectively.
Thus, this may be an outstanding feature among patients
with autism that points to their autoimmune background,
with the target in this case being the developing brain.
In our series, the finding of the increased frequency of
autoimmune diseases in the mothers of children with
autism (25%) was also in agreement with that of Comi
et al. [11] who reported an autoimmune disease in 16%
of the mothers of their studied patients with autism. The
high rate of autoimmune diseases in the mothers of the
children with autism could also suggest that an auto-
immune process exists in the mothers that targets the
developing fetus in utero. Although this would be more
consistent with the female preponderance in autoimmune
disorders, it does not explain the high male-to-female ratio
observed in autism [12].
The current study revealed a more significant increase
of the frequency of serum antinucleosome-specific anti-
bodies in autistic children with a family history of auto-
immunity (83.3%) than patients without such a history
(22.2%), P <0.001. This implies that in some families, im-
mune dysfunction, perhaps induced by certain environ-
mental triggers, could express itself in the form of
autism in one of its offspring. Immune-related genes in
the major histocompatibility complex (MHC) may play a
central role in the development of autoimmunity in aut-
ism. These genes have been associated with some auto-
immune diseases such as systemic lupus erythematous
and diabetes mellitus. A previous study reported thatmothers and their sons had a significantly higher frequency
of HLA-DR4 than normal control subjects [50].
To date, a definitive relationship between autism and
autoimmunity has not been fully established. On the
basis of the preliminary results reported in this study,
however, there seems to be a suggestion of evidence in
support of autoimmune contributions to the pathophysi-
ology of autism in some cases. Additional investigation
designed to expand on these data is warranted.
Conclusions
Serum levels of antinucleosome-specific antibodies were
increased in some autistic children. However, these data
should be treated with caution until further investiga-
tions are performed with a larger subject population to
determine whether these antibodies have a role in the
induction of autoimmunity in a subgroup of autistic
children. The role of immunotherapy in children with
autism should be also studied.
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